CG
XENE icon

Cutler Group’s Xenon Pharmaceuticals XENE Stock Holding History

Cutler Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100
Closed -$3K – 4840
2022
Q4 		$3K Hold
100
– – ﹤0.01% 3568
2022
Q3 		$3K Buy
+100
New +$3.6K ﹤0.01% 4075
2022
Q1 		– Sell
-600
Closed -$18K – 6168
2021
Q4 		$18K Sell
600
-1,293
-68% -$38.6K ﹤0.01% 3222
2021
Q3 		$28K Buy
1,893
+1,000
+112% +$17.4K ﹤0.01% 3052
2021
Q2 		$16K Buy
+893
New +$16.5K ﹤0.01% 3514
2020
Q4 		– Sell
-800
Closed -$9.36K – 5591
2020
Q3 		$8K Buy
+800
New +$9.41K ﹤0.01% 3191
2020
Q1 		– Sell
-969
Closed -$13.8K – 4762
2019
Q4 		$12K Buy
+969
New +$10.2K ﹤0.01% 2556

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Cutler Group's XENE Position: Q1 2023 in Review

Cutler Group sold out of Xenon Pharmaceuticals (XENE) in Q1 2023, closing a stake of 100 shares — an estimated $3K sold.

Cutler Group first reported a position in XENE in Q4 2019 and held it in 7 quarters. The position peaked at $28K in Q3 2021. 163 funds tracked by Wall St. Rank hold XENE as of Q1 2023.

  • Cutler Group reported no remaining Xenon Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 100 Xenon Pharmaceuticals shares in Q1 2023, an estimated $3K.
  • Cutler Group first reported a position in Xenon Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • Cutler Group's Xenon Pharmaceuticals position peaked at $28K in Q3 2021.
  • 163 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.